• Call for Abstracts
  • Call for Abstracts: Genome Editing, Health innovation, and Responsible Regulation

Nordic Permed Law Symposium and European Journal of Health Law (EJHL) special issue

NB! Please be informed that the abstract submission deadline is extended until August 7, 2021. You can submit your abstracts by 23:59 CEST this date. We are looking forward to seeing you in Uppsala /digitally if the pandemic requires that.

Nordic Permed Law is seeking original research contributions for a symposium on genome editing on 3-4 November 2021 and a subsequent special issue on Genome Editing, Health innovation, and Responsible Regulation for EJHL.

This special issue will be guest-edited by Santa Slokenberga, Ana Nordberg, and Timo Minssen on behalf of Nordic Permed Law. All contributions will be subject to double-blind peer-review, a review of guest editors, and a final check by the EJHL editorial board.

With the recent breakthroughs in genomics and advances in gene-editing techniques, the question of genome-editing and health innovation has become particularly important in society. New techniques such as CRISPR-Cas9 hold considerable potential to enhance personalized medicine. However, their potential and possible applications also bring along complex legal and regulatory questions in the European legal environment, intersecting with ethical and social concerns. How should the law respond to genome editing and health innovation in order to adequately reconcile diverse competing interests at stake and enhance personalized medicine?

We welcome submissions on the European legal perspectives of genome editing in health context and impacts for personalized medicine, including but not limited to topics falling within the following domains:

  • Research regulation

  • The right to health and transformation of medical care

  • Challenges surrounding fundamental concepts in health regulation

  • Diversity and vulnerabilities

  • Governance of genome editing in both health care and dual-uses of technology

  • The management of environmental health concerns posed by gene-editing technology

  • Market structures, personal data, and intellectual property rights in genomic medicine

Submission Process                                                   

We encourage submissions from both established and early-career legal scholars. Interested authors should provide an abstract of no more than 300 words in Word format and provide the following information: first name/surname, affiliation, the title of the proposed paper, and email address of the corresponding author. We kindly ask you to confirm your availability for the symposium and preference for either a presentation on site in Uppsala, Sweden (if the public health regulations allow for that) or via a digital solution.

Please email your abstract by 1 August 2021 to post@nordicpermedlaw.org. Candidates will be notified by 9 August 2021 about the editors’ decision. If the proposal is accepted, the draft manuscript must be circulated among the participants of the symposium by the 21 of October 2021 and the full article must be submitted by 17 December 2021.

Manuscripts should not exceed 9,500 words including footnotes and follow the EJHL author guidelines: https://brill.com/fileasset/downloads_products/Author_Instructions/EJHL.pdf

Warm wishes,

Santa Slokenberga, Ana Nordberg and Timo Minssen on behalf of the Nordic Permed Law

Santa Slokenberga

LL.D., Senior Lecturer in Administrative Law, Faculty of Law, Uppsala University

Headshot of Santa Slokenberga.

Ana Nordberg

Associate Professor, Faculty of Law, Lund University

Headshot of Ana Nordberg.

Timo Minssen

Prof. Dr., LL.Lic., LL.M., M.I.C.L., Dipl. Jur., Faculty of Law, University of Copenhagen. Managing Director, Centre for Advanced Studies in Biomedical Innovation Law (CeBIL)

Timo Minssen.